Trials / Not Yet Recruiting

Not Yet RecruitingNCT06961721

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IV Clinical Trial to Evaluate the Immunogenicity and Safety of a Live Attenuated Herpes Zoster Vaccine in Adults Aged 40 Years and Older

Status: Not Yet Recruiting
Phase: Phase 4
Study type: Interventional
Enrollment: 600 (estimated)

Sponsor: Changchun BCHT Biotechnology Co. · Industry
Sex: All
Age: 40 Years
Healthy volunteers: Accepted

Summary

To evaluate the immunogenicity 42 days after vaccination with the live attenuated herpes zoster vaccine. To evaluate the safety of the live attenuated herpes zoster vaccine.

Conditions

Prevention of Herpes Zoster

Interventions

Type	Name	Description
BIOLOGICAL	Herpes Zoster Vaccine, Live	assigned to the vaccine group and placebo group in a 2:1 ratio.
BIOLOGICAL	Placebo	assigned to the vaccine group and placebo group in a 2:1 ratio.

Timeline

Start date: 2025-05-01
Primary completion: 2025-07-01
Completion: 2025-12-01
First posted: 2025-05-08
Last updated: 2025-05-08

Source: ClinicalTrials.gov record NCT06961721. Inclusion in this directory is not an endorsement.